Specificity assessment of CRISPR genome editing of oncogenic EGFR point mutation with single-base differences

Taegeun Bae, Hanseop Kim, Jeong Hee Kim, Yong Jun Kim, Seung Hwan Lee, Byung Joo Ham, Junho K. Hur

Research output: Contribution to journalArticle

Abstract

In CRISPR genome editing, CRISPR proteins form ribonucleoprotein complexes with guide RNAs to bind and cleave the target DNAs with complete sequence complementarity. CRISPR genome editing has a high potential for use in precision gene therapy for various diseases, including cancer and genetic disorders, which are caused by DNA mutations within the genome. However, several studies have shown that targeting the DNA via sequence complementarity is imperfect and subject to unintended genome editing of other genomic loci with similar sequences. These off-target problems pose critical safety issues in the therapeutic applications of CRISPR technology, with particular concerns in terms of the genome editing of pathogenic point mutations, where non-mutant alleles can become an off-target with only a one-base difference. In this study, we sought to assess a novel CRISPR genome editing technique that has been proposed to achieve a high specificity by positioning the mismatches within the protospacer adjacent motif (PAM) sequence. To this end, we compared the genome editing specificities of the PAM-based and conventional methods on an oncogenic single-base mutation in the endothelial growth factor receptor (EGFR). The results indicated that the PAM-based method provided a significantly increased genome editing specificity for pathogenic mutant alleles with single-base precision.

Original languageEnglish
Article number52
JournalMolecules
Volume25
Issue number1
DOIs
Publication statusPublished - 2020 Jan 1

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
editing
Vascular Endothelial Growth Factor Receptor
genome
mutations
Point Mutation
Genes
deoxyribonucleic acid
Guide RNA
Alleles
DNA
Mutation
Inborn Genetic Diseases
gene therapy
Ribonucleoproteins
Gene therapy
Gene Editing
Genetic Therapy
loci
positioning

Keywords

  • CRISPR
  • Off-target
  • PAM
  • Single-base precision
  • Specificity

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this

Specificity assessment of CRISPR genome editing of oncogenic EGFR point mutation with single-base differences. / Bae, Taegeun; Kim, Hanseop; Kim, Jeong Hee; Kim, Yong Jun; Lee, Seung Hwan; Ham, Byung Joo; Hur, Junho K.

In: Molecules, Vol. 25, No. 1, 52, 01.01.2020.

Research output: Contribution to journalArticle

Bae, Taegeun ; Kim, Hanseop ; Kim, Jeong Hee ; Kim, Yong Jun ; Lee, Seung Hwan ; Ham, Byung Joo ; Hur, Junho K. / Specificity assessment of CRISPR genome editing of oncogenic EGFR point mutation with single-base differences. In: Molecules. 2020 ; Vol. 25, No. 1.
@article{7bc742e212c04b25bdce005c9fa169fa,
title = "Specificity assessment of CRISPR genome editing of oncogenic EGFR point mutation with single-base differences",
abstract = "In CRISPR genome editing, CRISPR proteins form ribonucleoprotein complexes with guide RNAs to bind and cleave the target DNAs with complete sequence complementarity. CRISPR genome editing has a high potential for use in precision gene therapy for various diseases, including cancer and genetic disorders, which are caused by DNA mutations within the genome. However, several studies have shown that targeting the DNA via sequence complementarity is imperfect and subject to unintended genome editing of other genomic loci with similar sequences. These off-target problems pose critical safety issues in the therapeutic applications of CRISPR technology, with particular concerns in terms of the genome editing of pathogenic point mutations, where non-mutant alleles can become an off-target with only a one-base difference. In this study, we sought to assess a novel CRISPR genome editing technique that has been proposed to achieve a high specificity by positioning the mismatches within the protospacer adjacent motif (PAM) sequence. To this end, we compared the genome editing specificities of the PAM-based and conventional methods on an oncogenic single-base mutation in the endothelial growth factor receptor (EGFR). The results indicated that the PAM-based method provided a significantly increased genome editing specificity for pathogenic mutant alleles with single-base precision.",
keywords = "CRISPR, Off-target, PAM, Single-base precision, Specificity",
author = "Taegeun Bae and Hanseop Kim and Kim, {Jeong Hee} and Kim, {Yong Jun} and Lee, {Seung Hwan} and Ham, {Byung Joo} and Hur, {Junho K.}",
year = "2020",
month = "1",
day = "1",
doi = "10.3390/molecules25010052",
language = "English",
volume = "25",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - Specificity assessment of CRISPR genome editing of oncogenic EGFR point mutation with single-base differences

AU - Bae, Taegeun

AU - Kim, Hanseop

AU - Kim, Jeong Hee

AU - Kim, Yong Jun

AU - Lee, Seung Hwan

AU - Ham, Byung Joo

AU - Hur, Junho K.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - In CRISPR genome editing, CRISPR proteins form ribonucleoprotein complexes with guide RNAs to bind and cleave the target DNAs with complete sequence complementarity. CRISPR genome editing has a high potential for use in precision gene therapy for various diseases, including cancer and genetic disorders, which are caused by DNA mutations within the genome. However, several studies have shown that targeting the DNA via sequence complementarity is imperfect and subject to unintended genome editing of other genomic loci with similar sequences. These off-target problems pose critical safety issues in the therapeutic applications of CRISPR technology, with particular concerns in terms of the genome editing of pathogenic point mutations, where non-mutant alleles can become an off-target with only a one-base difference. In this study, we sought to assess a novel CRISPR genome editing technique that has been proposed to achieve a high specificity by positioning the mismatches within the protospacer adjacent motif (PAM) sequence. To this end, we compared the genome editing specificities of the PAM-based and conventional methods on an oncogenic single-base mutation in the endothelial growth factor receptor (EGFR). The results indicated that the PAM-based method provided a significantly increased genome editing specificity for pathogenic mutant alleles with single-base precision.

AB - In CRISPR genome editing, CRISPR proteins form ribonucleoprotein complexes with guide RNAs to bind and cleave the target DNAs with complete sequence complementarity. CRISPR genome editing has a high potential for use in precision gene therapy for various diseases, including cancer and genetic disorders, which are caused by DNA mutations within the genome. However, several studies have shown that targeting the DNA via sequence complementarity is imperfect and subject to unintended genome editing of other genomic loci with similar sequences. These off-target problems pose critical safety issues in the therapeutic applications of CRISPR technology, with particular concerns in terms of the genome editing of pathogenic point mutations, where non-mutant alleles can become an off-target with only a one-base difference. In this study, we sought to assess a novel CRISPR genome editing technique that has been proposed to achieve a high specificity by positioning the mismatches within the protospacer adjacent motif (PAM) sequence. To this end, we compared the genome editing specificities of the PAM-based and conventional methods on an oncogenic single-base mutation in the endothelial growth factor receptor (EGFR). The results indicated that the PAM-based method provided a significantly increased genome editing specificity for pathogenic mutant alleles with single-base precision.

KW - CRISPR

KW - Off-target

KW - PAM

KW - Single-base precision

KW - Specificity

UR - http://www.scopus.com/inward/record.url?scp=85077281192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077281192&partnerID=8YFLogxK

U2 - 10.3390/molecules25010052

DO - 10.3390/molecules25010052

M3 - Article

C2 - 31877894

AN - SCOPUS:85077281192

VL - 25

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 1

M1 - 52

ER -